These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 25360720)

  • 1. A quality by design approach for longitudinal quality attributes.
    Lebrun P; Giacoletti K; Scherder T; Rozet E; Boulanger B
    J Biopharm Stat; 2015; 25(2):247-59. PubMed ID: 25360720
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analytical procedure validation and the quality by design paradigm.
    Rozet E; Lebrun P; Michiels JF; Sondag P; Scherder T; Boulanger B
    J Biopharm Stat; 2015; 25(2):260-8. PubMed ID: 25357001
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dissolution curve comparisons through the F(2) parameter, a Bayesian extension of the f(2) statistic.
    Novick S; Shen Y; Yang H; Peterson J; LeBlond D; Altan S
    J Biopharm Stat; 2015; 25(2):351-71. PubMed ID: 25357203
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Guest editors' note: special issue on recent developments in statistical approaches for chemistry and manufacturing control (CMC) and quality-by-design(QbD).
    Tsong Y; Yang H
    J Biopharm Stat; 2015; 25(2):233. PubMed ID: 25437635
    [No Abstract]   [Full Text] [Related]  

  • 5. Using tolerance intervals for assessment of pharmaceutical quality.
    Dong X; Tsong Y; Shen M; Zhong J
    J Biopharm Stat; 2015; 25(2):317-27. PubMed ID: 25356617
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Statistical considerations in setting product specifications.
    Dong X; Tsong Y; Shen M
    J Biopharm Stat; 2015; 25(2):280-94. PubMed ID: 25358110
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quality assurance test of delivered dose uniformity of multiple-dose inhaler and dry powder inhaler drug products.
    Tsong Y; Dong X; Shen M; Lostritto RT
    J Biopharm Stat; 2015; 25(2):328-38. PubMed ID: 25357132
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Bayesian design space for analytical methods based on multivariate models and predictions.
    Lebrun P; Boulanger B; Debrus B; Lambert P; Hubert P
    J Biopharm Stat; 2013; 23(6):1330-51. PubMed ID: 24138435
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Testing assay linearity over a pre-specified range.
    Yang H; Novick SJ; LeBlond D
    J Biopharm Stat; 2015; 25(2):339-50. PubMed ID: 25356663
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A statistical approach to determining criticality of residual host cell DNA.
    Yang H; Wei Z; Schenerman M
    J Biopharm Stat; 2015; 25(2):234-46. PubMed ID: 25358029
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Bayesian approach to the ICH Q8 definition of design space.
    Peterson JJ
    J Biopharm Stat; 2008; 18(5):959-75. PubMed ID: 18781528
    [TBL] [Abstract][Full Text] [Related]  

  • 12. One- and two-stage Arrhenius models for pharmaceutical shelf life prediction.
    Fan Z; Zhang L
    J Biopharm Stat; 2015; 25(2):307-16. PubMed ID: 25358076
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design space approach in the optimization of the spray-drying process.
    Lebrun P; Krier F; Mantanus J; Grohganz H; Yang M; Rozet E; Boulanger B; Evrard B; Rantanen J; Hubert P
    Eur J Pharm Biopharm; 2012 Jan; 80(1):226-34. PubMed ID: 21983606
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quality by design approach for formulation development: a case study of dispersible tablets.
    Charoo NA; Shamsher AA; Zidan AS; Rahman Z
    Int J Pharm; 2012 Feb; 423(2):167-78. PubMed ID: 22209997
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-normal random effects models for immunogenicity assay cut point determination.
    Zhang J; Yu B; Zhang L; Roskos L; Richman L; Yang H
    J Biopharm Stat; 2015; 25(2):295-306. PubMed ID: 25356500
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of raw material properties upon critical quality attributes of continuously produced granules and tablets.
    Fonteyne M; Wickström H; Peeters E; Vercruysse J; Ehlers H; Peters BH; Remon JP; Vervaet C; Ketolainen J; Sandler N; Rantanen J; Naelapää K; De Beer T
    Eur J Pharm Biopharm; 2014 Jul; 87(2):252-63. PubMed ID: 24589422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Statistical evaluation of several methods for cut-point determination of immunogenicity screening assay.
    Shen M; Dong X; Tsong Y
    J Biopharm Stat; 2015; 25(2):269-79. PubMed ID: 25356783
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integrated Application of Quality-by-Design Principles to Drug Product Development: A Case Study of Brivanib Alaninate Film-Coated Tablets.
    Badawy SI; Narang AS; LaMarche KR; Subramanian GA; Varia SA; Lin J; Stevens T; Shah PA
    J Pharm Sci; 2016 Jan; 105(1):168-81. PubMed ID: 26852852
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Kinetic modeling on drug release from controlled drug delivery systems.
    Dash S; Murthy PN; Nath L; Chowdhury P
    Acta Pol Pharm; 2010; 67(3):217-23. PubMed ID: 20524422
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new roadmap for biopharmaceutical drug product development: Integrating development, validation, and quality by design.
    Martin-Moe S; Lim FJ; Wong RL; Sreedhara A; Sundaram J; Sane SU
    J Pharm Sci; 2011 Aug; 100(8):3031-3043. PubMed ID: 21425164
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.